v3.26.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Revenue (note 12) $ 9,830 $ 5,289 $ 17,650 $ 10,121
Cost of sales 2,150 1,358 4,191 2,719
Gross profit 7,680 3,931 13,459 7,402
Operating expenses        
Research and development 5,806 5,418 16,722 16,324
Selling, general and administrative 9,695 7,426 23,645 24,963
Total operating expenses 15,501 12,844 40,367 41,287
Operating loss 7,821 8,913 26,908 33,885
Other (income) expenses        
Net finance income (196) (122) (909) (910)
Net foreign exchange (gain) loss 101 (935) (1,760) 1,194
Total other (income) expenses (95) (1,057) (2,669) 284
Net loss before income taxes 7,726 7,856 24,239 34,169
Income tax expense 8 100 103 219
Deferred tax (recovery) expense (12) 21 (27) 7
Total income tax (recovery) expense (4) 121 76 226
Net loss attributed to shareholders for the period 7,722 7,977 24,315 34,395
Item that may be reclassified to (income) loss        
Foreign currency translation adjustment (134) 808 1,821 (2,008)
Net loss and other comprehensive loss for the period $ 7,588 $ 8,785 $ 26,136 $ 32,387
Loss per share (note 13)        
Basic net loss per common share (in dollars per share) $ 0.21 $ 0.26 $ 0.67 $ 1.14
Diluted net loss per common share (in dollars per share) $ 0.21 $ 0.26 $ 0.67 $ 1.14
Basic weighted average common shares outstanding (in shares) 36,556,064 30,104,497 36,402,550 30,119,569
Diluted weighted average common shares outstanding (in shares) 36,556,064 30,104,497 36,402,550 30,119,569
Recurring - non-capital        
Revenue (note 12) $ 4,106 $ 4,066 $ 8,192 $ 7,428
Capital equipment        
Revenue (note 12) $ 5,724 $ 1,223 $ 9,458 $ 2,693